中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
23期
3560-3562
,共3页
高脂血症%载脂蛋白B%基因,突变%阿托伐他汀
高脂血癥%載脂蛋白B%基因,突變%阿託伐他汀
고지혈증%재지단백B%기인,돌변%아탁벌타정
Hyperlipemia%Apolipoprotein B%Gene,mutations%Atorvastatin
目的 探讨载脂蛋白B(ApoB)基因突变对阿托伐他汀调脂作用的影响.方法 选取152例高脂血症患者为研究对象,采用聚合酶链反应-限制性内切片段长度多态性(PCR-RFLP)方法检测高脂血症患者ApoB基因多态性.所有患者给予阿托伐他汀治疗,分别在治疗前后采用酶法测定血脂水平.分析不同基因型(非X+携带者和X+携带者)患者的血脂水平[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)].结果 非X+携带者治疗前后TC、LDL-C下降百分比分别为(28.98±5.21)％,LDL-C下降百分比为(32.67±7.19)％,均大于X+携带者的(18.97±4.01)％、(26.07±3.45)％(均P＜0.05).非X+携带者治疗前后TG下降百分比和HDL-C升高百分比与X+携带者比较差异均无统计学意义(均P＞0.05).结论 ApoB基因变异影响高脂血症患者的血清TC和LDL-C水平,X+携带者的血脂水平较非X+携带者高;且阿托伐他汀对X+携带者的调脂作用较弱.
目的 探討載脂蛋白B(ApoB)基因突變對阿託伐他汀調脂作用的影響.方法 選取152例高脂血癥患者為研究對象,採用聚閤酶鏈反應-限製性內切片段長度多態性(PCR-RFLP)方法檢測高脂血癥患者ApoB基因多態性.所有患者給予阿託伐他汀治療,分彆在治療前後採用酶法測定血脂水平.分析不同基因型(非X+攜帶者和X+攜帶者)患者的血脂水平[總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)].結果 非X+攜帶者治療前後TC、LDL-C下降百分比分彆為(28.98±5.21)％,LDL-C下降百分比為(32.67±7.19)％,均大于X+攜帶者的(18.97±4.01)％、(26.07±3.45)％(均P＜0.05).非X+攜帶者治療前後TG下降百分比和HDL-C升高百分比與X+攜帶者比較差異均無統計學意義(均P＞0.05).結論 ApoB基因變異影響高脂血癥患者的血清TC和LDL-C水平,X+攜帶者的血脂水平較非X+攜帶者高;且阿託伐他汀對X+攜帶者的調脂作用較弱.
목적 탐토재지단백B(ApoB)기인돌변대아탁벌타정조지작용적영향.방법 선취152례고지혈증환자위연구대상,채용취합매련반응-한제성내절편단장도다태성(PCR-RFLP)방법검측고지혈증환자ApoB기인다태성.소유환자급여아탁벌타정치료,분별재치료전후채용매법측정혈지수평.분석불동기인형(비X+휴대자화X+휴대자)환자적혈지수평[총담고순(TC)、감유삼지(TG)、저밀도지단백담고순(LDL-C)、고밀도지단백담고순(HDL-C)].결과 비X+휴대자치료전후TC、LDL-C하강백분비분별위(28.98±5.21)％,LDL-C하강백분비위(32.67±7.19)％,균대우X+휴대자적(18.97±4.01)％、(26.07±3.45)％(균P＜0.05).비X+휴대자치료전후TG하강백분비화HDL-C승고백분비여X+휴대자비교차이균무통계학의의(균P＞0.05).결론 ApoB기인변이영향고지혈증환자적혈청TC화LDL-C수평,X+휴대자적혈지수평교비X+휴대자고;차아탁벌타정대X+휴대자적조지작용교약.
Objective To explore the influence of Apolipoprotein B(ApoB)gene mutations on the lipid-regulating effect of atorvastatin in patients with hyperlipidemia.Methods 152 patients with hyperlipidemia were selected as the research targets,the ApoB gene polymorphism was detected by polymerase chain reaction-restrictive cut inside fragment length polymorphism(PCR-RFLP)method.All the patients given atorvastatin treatment,and determined lipid levels before and after treatment.Then the lipid level[total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]of the different genotypes(no X+carriers and X+carriers)of patients were analyzed.Results The percentage decline of TC and LDL-C of no X+carriers was(28.98±5.21)％,(32.67±7.19)％,respectively,which were higher than those of X+carriers[(18.97±4.01)％ and(26.07±3.45)％](P＜0.05).The percentage decline of TG and increasing of HDL-C of no X+cartiers had no significance difference with those of X+carriers(all P＞0.05).Conclusion ApoB gene mutation influence serum TC and LDL-C levels of hypedipidemia patients,the levels of TC and LDL-C of X+carriers are higher than those of no X+carriers;And the lipid-regulating effect of atorvastatin for X+carriers is more weaker.
